|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2003-8-6
|
|
pubmed:abstractText |
Paclitaxel administered in combination with a topoisomerase-II inhibitor (such as etoposide) and carboplatin is an effective and safe first-line treatment for patients with small-cell lung cancer (SCLC). We conducted a randomized phase III multicenter trial to determine whether paclitaxel plus etoposide plus carboplatin improves the outcome of patients with primary SCLC relative to standard chemotherapy (carboplatin, etoposide, and vincristine).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1460-2105
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
6
|
|
pubmed:volume |
95
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1118-27
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12902441-Adult,
pubmed-meshheading:12902441-Aged,
pubmed-meshheading:12902441-Analysis of Variance,
pubmed-meshheading:12902441-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12902441-Carboplatin,
pubmed-meshheading:12902441-Carcinoma, Small Cell,
pubmed-meshheading:12902441-Disease Progression,
pubmed-meshheading:12902441-Disease-Free Survival,
pubmed-meshheading:12902441-Drug Administration Schedule,
pubmed-meshheading:12902441-Etoposide,
pubmed-meshheading:12902441-Female,
pubmed-meshheading:12902441-Hematologic Diseases,
pubmed-meshheading:12902441-Humans,
pubmed-meshheading:12902441-Lung Neoplasms,
pubmed-meshheading:12902441-Male,
pubmed-meshheading:12902441-Middle Aged,
pubmed-meshheading:12902441-Neoplasm Staging,
pubmed-meshheading:12902441-Paclitaxel,
pubmed-meshheading:12902441-Patient Selection,
pubmed-meshheading:12902441-Prognosis,
pubmed-meshheading:12902441-Proportional Hazards Models,
pubmed-meshheading:12902441-Risk Factors,
pubmed-meshheading:12902441-Survival Analysis,
pubmed-meshheading:12902441-Treatment Outcome,
pubmed-meshheading:12902441-Vincristine
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer.
|
|
pubmed:affiliation |
Department of Thoracic Oncology, Hospital Grosshansdorf, Hamburg, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
